AZTA

Azenta, Inc. (AZTA) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This filing covers the quarterly period ended March 31, 2026 (Fiscal Q2 2026). Azenta, Inc. is a global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The company operates through two primary segments: Sample Management Solutions (SMS) and Multiomics. The reporting period is significantly impacted by a pending divestiture of the B Medical Systems business (classified as discontinued operations) and a major goodwill impairment charge.

Key Financial Metrics

Material Changes vs. Prior Period

• Goodwill Impairment: The company recorded a non-cash impairment charge of $149.1 million ($36.6 million for SMS and $112.4 million for Multiomics) due to a decline in stock price and revised forecasts. This is the primary driver of the increased operating loss.
• Revenue Growth: Total revenue increased slightly by 1.0% year-over-year for the quarter and 0.9% year-over-year for the six-month period, driven by growth in Sample Storage and Next Generation Sequencing services.
• Margin Compression: Gross margin decreased to 42.8% (Q2) and 42.9% (YTD) from 43.8% and 45.3% in the prior year, attributed to lost fixed-cost leverage in Sanger Sequencing and higher rework costs on Automated Stores projects.
• Discontinued Operations: The B Medical Systems business is classified as held for sale. The transaction with Thelema S.à R.L. did not close by March 31, 2026, due to financing delays. A $9.0 million deposit was received, with a potential $5.0 million break-up fee if terminated.
• Acquisition: Azenta acquired UK Biocentre Limited for approximately $27.5 million (net of cash) on March 4, 2026, recognizing a $3.9 million non-cash gain from settling a preexisting contractual relationship.

Guidance, Outlook, and Risks

• Divestiture Uncertainty: The sale of B Medical Systems remains subject to the buyer securing financing. Failure to close could result in continued operational costs and potential additional impairment charges.
• Internal Controls: The company disclosed that disclosure controls and procedures were not effective as of March 31, 2026, due to material weaknesses in cash flow statement review, account reconciliations, and expense classification. Remediation plans are underway but not yet sufficient to assert remediation.
• Future Impairments: Management warned that if performance does not meet expectations or market conditions worsen, additional impairment charges may be required.
• Liquidity: The company holds $564.8 million in cash, cash equivalents, and marketable securities, with no outstanding debt. Management believes this is sufficient to fund operations for at least one year.
• Share Repurchase: A new $250 million share repurchase program was authorized in December 2025; no shares have been repurchased under this program to date.

Investor Verification Checklist

• Impairment Methodology: Verify the assumptions used in the quantitative goodwill impairment test (discount rates, growth forecasts) for the SMS and Multiomics segments.
• B Medical Systems Status: Monitor updates on Thelema's financing status and the likelihood of the $54.0 million remaining payment being secured.
• Internal Control Remediation: Review progress on fixing material weaknesses regarding cash flow reporting and expense classification to ensure future financial statement reliability.
• UK Biocentre Integration: Assess the impact of the UK Biocentre acquisition on the SMS segment's revenue and margin profile in subsequent quarters.
• Discontinued Operations Losses: Confirm the final loss on assets held for sale related to B Medical Systems as the transaction timeline extends.